The Future of Cogent Biosciences Inc: Analyzing COGT

In terms of market performance, Cogent Biosciences Inc had a fairly uneven. The highest value for the stock in the past year was $15.01 on 02/10/23, and the lowest value was recorded at $3.67 on 12/11/23.

52-week price history of COGT Stock

Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Cogent Biosciences Inc’s current trading price is -60.83% away from its 52-week high, while its distance from the 52-week low is 60.22%. The stock’s price range during the 52-week period has remained between $3.67 and $15.01. In the Healthcare sector, the company’s shares saw a trading volume of around 1.97 for the day, which was evidently higher than the average daily volume of 0.84 over the past three months.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Market Capitalization and Financial Performance: An In-Depth Look

Cogent Biosciences Inc (COGT) has experienced a quarterly decline of -20.05% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 506.39M.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 7.16, with a change in price of -4.85. Similarly, Cogent Biosciences Inc recorded 1,537,325 in trading volume during the last 100 days, posting a change of -45.20%.

Examining COGT’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for COGT stands at 0.06. Similarly, the long-term debt-to-equity ratio is also 0.06.

COGT Stock Stochastic Average

Cogent Biosciences Inc’s raw stochastic average for the past 50 days is presently 37.59%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 68.48%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 79.80% and 83.44%, respectively.

COGT Stock Price Performance Analysis

The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Until today this year the stock’s price performance recorded a decrease of 0.00%. However, over the last six months, the performance has been stronger by -51.08%. The price of COGT increased 10.32% over the last 30 days. And in the last five days, it has surged by 22.50%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts